Presently, five years after transplant, the patient is alive in continued complete remission.
EBV is a highly immunogenic γ-herpesvirus. Severely immunosuppressed patients develop B-cell proliferation and diminished EBV-specific cytotoxic T-cell population [3] . EBV-associated B-cell PTLD is a life-threatening complication after alloHSCT resulting from an outgrowth of infected donor-origin B cells [3] . In HSCT patients EBV is a second, after Human herpesvirus 6, viral encephalitis etiology [4] . HLH, characterized by molecular abnormalities or/and clinical/laboratory criteria: fever, splenomegaly, cytopenia, reduced NK cells activity, hypofibrinogenemia, increased sCD25, ferritin and triglycerides and hemophagocytosis, has become more widely recognized in adults, dominated by secondary forms of the disease [5] . The EBV-driven HLH treatment strategy depends on the patient's condition, from short course corticosteroids with or without immunoglobulins in less severe disease to intensive treatment with early etoposide application in rapidly deteriorating patients [5] . There is no established standard of care in patients fulfilling HLH-2004 diagnostic criteria after alloHSCT. In the above patient, based on high EBV load and imaging, probable PTLD was diagnosed, complicated by HLH. EBV meningoencephalitis and advanced central nervous system HLH involvement may by differentiated. Focusing on HLH as a major lifethreating event, adoption of HLH2004 regimen modalities provided an excellent clinical outcome in rituximab refractory disease. However, negative pre-transplant donor EBV immunity status and co-reactivating viruses may impede treatment. 
